舒利迭治疗慢性阻塞性肺疾病的疗效观察

目的 对比研究舒利迭(沙美特罗/丙酸氟替卡松)治疗稳定期严重程度为Ⅲ-Ⅳ级的慢性阻塞性肺疾病(COPD)的疗效.方法 对160例确诊为COPD的患者随机分为2组:分别吸入舒利迭(试验组)、辅舒酮加万托林(对照组),疗程6个月,测定肺功能指标FEV1,FEV1/FVC,FEV1占预计值百分比(%),评价治疗前后肺功能的变化.结果 与应用辅舒酮加万托林组比较,舒利迭组治疗后肺功能指标改善显著(P＜0.05).结论 舒利迭对稳定期严重程度为Ⅲ-Ⅳ级COPD患者的疗效明显优于其他复合制剂,是目前临床治疗COPD的最有效的药物.

Observation on Seretide in Treatment of Chronic Obstructive Pulmonary Diseases

Objective To investigate the curative effect of seretide(salmeterol/fluticasome propionate on lung function of the patients with chronic obstructive pulmonary diseases(COPD).Methods 160 patients who suffered from COPD were divided into 2 groups:experiment group(inhale seretde),control group(inhale flixotde and albuterol aerosol). Both were treated for six months.Subsequently,the percentage of pulmonary functional parameters including FEV1,FEVI orFVC andFEVI in the anticipation value(%) were examined and then the pulmonary functional changes before and after therapy were evaluated Results Clinical symptom integral and the above-mentioned poulmonary functional param-eters in the seretide group were improved more significantly than those in the flixotide and albuterol aerosol group(P<0.005).Conclusions Seretide can presently serve as the most ideal medicine for COPD due to its more significant curative effect than the other compound preparation.